You are here: Industry Insights > Catalent

News List

DisperSol, Catalent Enter Manufacturing Collaboration contractpharma
August 04, 2021
DisperSol Technologies, a clinical-stage pharmaceutical company developing new treatments for oncology and rare diseases, and Catalent, a global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics ...
Catalent Launches New OptiDose Design Solution contractpharma
July 27, 2021
Aims to help craft the ideal dose form for all stakeholders and optimize the potential of a molecule.
Catalent Biologics Launches GPEx Lightning Cell Line Expression Technology contractpharma
July 23, 2021
Designed to shorten drug substance development timelines by up to three months.
Catalent Plans $100M Expansion of Biologics Mfg. Capabilities in Italy contractpharma
July 22, 2021
Initial phase includes installation of two 2,000-liter single-use bioreactors and associated investments to support early-and late-phase clinical development.
Catalent plans $100 million biologics manufacturing expansion at Anagni cphi-online
July 22, 2021
Two 2,000-liter single-use bioreactors to be installed as part of first phase expected to be operational in April 2023
Curtana and Catalent Enter Brain Cancer Drug Partnership contractpharma
July 19, 2021
Curtana has signed an agreement with Catalent to support tablet formulation and manufacturing of Curtana’s CT-179, a drug therapy for the treatment of glioblastoma (GBM), medulloblastoma (MB), and other brain cancers.
Catalent enters CBD anaesthetic product formulation project cphi-online
July 19, 2021
The company will use its orally disintegrating tablet technology Zydis for JOS Pharmaceuticals' licensed CBD product
Catalent, JOS Pharmaceuticals Enter Zydis Formulation Agreement contractpharma
July 14, 2021
Catalent to undertake a feasibility study for the potential development of a CBD product for use as an anesthetic leveraging its ODT technology.
Catalent to Acquire RheinCell Therapeutics contractpharma
June 28, 2021
Catalent, a global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, has reached an agreement to acquire RheinCell Therapeutics GmbH ...
HBC, Catalent Enter Innovative Softgel Alliance contractpharma
May 13, 2021
Hofseth BioCare ASA (HBC), a Norwegian biotech company that develops high-value ingredients and finished products, entered a global innovation partnership with Catalent to develop a delayed-release formulation of HBC’s OmeGo fish oil.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page